1
Clinical Trials associated with Autologous bone marrow derived MSCs therapy(Stem Med Pte)Mesenchymal Stem Cell Therapy for Liver Cirrhosis: A Phase I/II Study
MSCs have been studied for the treatment of liver diseases as well as non-liver diseases. MSCs have been successful in treating conditions like acute steroid-resistant GVHD in hematopoietic stem cell transplanted patients and also have shown to improve the MELD score in end-stage liver disease. There were no severe side effects observed in using autologous MSCs as a treatment option. The outcome of the studies done so far have been positive and it is encouraged to study the use of MSCs as cell therapy for treating liver diseases.
The estimated rate of cirrhosis in HBV patients in Singapore is about 1.6% per year, rate of hepatocellular carcinoma is about 0.8% per year overall and 3.0% per year in cirrhotic patients. Knowing that there are not many options currently available for Liver Cirrhosis patients and that they have a poor prognosis with an average life expectancy of < 12 months, this study uses autologous MSCs to treat Liver Cirrhosis patients in Singapore. The objective of the study is to demonstrate that autologous bone marrow is safe to be used in patients with liver cirrhosis as well as demonstrate that bone marrow MSC may improve liver function and prolong patient survival.
100 Clinical Results associated with Autologous bone marrow derived MSCs therapy(Stem Med Pte)
100 Translational Medicine associated with Autologous bone marrow derived MSCs therapy(Stem Med Pte)
100 Patents (Medical) associated with Autologous bone marrow derived MSCs therapy(Stem Med Pte)
100 Deals associated with Autologous bone marrow derived MSCs therapy(Stem Med Pte)